17 jul: GreenMobility udvider til Storbritannien og indgår LOI med lokal ..
18 jul: Indre værdi af SmallCap Danmark A/S er opgjort til 10,4 kr. pr. a..
18-07-2019 02:30:00

Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States

Company Announcement

  • Genmab has today announced the pricing of its initial public offering of ADSs and the listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB”

  • Genmab has applied to change the trading symbol of its ordinary shares on Nasdaq Copenhagen from “GEN” to “GMAB” in connection with the admission to trading of the ordinary shares underlying the ADSs on Nasdaq Copenhagen

             

Copenhagen, Denmark; July 18, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today the pricing of its initial public offering of American Depositary Shares (ADSs) in the United States (the “Offering”) and the listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB.” The offering will produce gross proceeds of $505,875,000 from the sale of 2,850,000 ordinary shares of Genmab in the form of 28,500,000 ADSs at a price of $17.75 per ADS. Each ADS will represent one-tenth of one ordinary share of Genmab. In addition, Genmab has granted the underwriters an option to purchase up to 4,275,000 additional ADSs, representing 427,500 ordinary shares to cover any over-allotments (the “Option”). The Option can be exercised during the 30-day period commencing July 17, 2019.

In connection with the anticipated listing of our ADSs on the Nasdaq Global Select Market, we have requested that Nasdaq Copenhagen change the symbol for our ordinary shares from “GEN” to “GMAB” to become effective in connection with the admission to trading of the ordinary shares underlying the ADSs on Nasdaq Copenhagen, expected to occur on July 23, 2019.

Summary of the Offering:

  • The Offering will consist of an offering of a total of 28,500,000 ADSs, corresponding to 2,850,000 underlying ordinary shares of Genmab (the “New Shares”), which in their entirety are expected to be subscribed for by BofA Merrill Lynch, Morgan Stanley and Jefferies (the “Joint Book-Running Managers”), as representatives of the several underwriters, with an instruction to deliver such new shares to Deutsche Bank Trust Company Americas acting as depositary for the underlying New Shares in the Offering;
  • The public offering price is $17.75 per ADS, corresponding to a subscription price of DKK 1,181.80 per underlying ordinary share at an exchange rate of DKK 6.6580 per US$1.00 on July 17, 2019, multiplied by the ADS-to-share ratio of 10 to 1;
  • The Joint Book-Running Managers, as representatives of the several underwriters, have been granted an Option to acquire an additional 4,275,000 ADSs, exercisable in whole or in part through August 16, 2019 to cover over-allotments.
  • The New Shares underlying the ADSs will correspond to 4.4% of Genmab's entire share capital assuming no exercise of the Option and 5.0% of Genmab's entire share capital assuming full exercise of the Option;
  • Gross proceeds from the Offering will amount to $505.9 million (DKK 3,368.1 million) assuming no exercise of the Option and $581.8 million (DKK 3,873.3 million) assuming full exercise of the Option;
  • Allocation of the ADSs has been determined by the board of directors in consultation with the Joint Book-Running Managers; and
  • A timetable of expected future principal events can be seen below:

Event

Expected date

The ADSs start trading on the Nasdaq Global Select Market...July 18, 2019
Filing in the United States of the final prospectus ………….....July 18, 2019
Closing of the Offering ……………………………………………July 22, 2019
Registration of the New Shares underlying the ADSs

with the Danish Business Authority ……………………………..

 

July 22, 2019

Admission for listing of the New Shares underlying the

ADSs on Nasdaq Copenhagen ………………….......................

 

July 23, 2019

In addition, Genmab announced that the board of directors of Genmab has today determined (i) to increase the size of the Offering from up to 27,800,000 ADSs to a total of 28,500,000 ADSs, and to issue a total of 28,500,000 ADSs (excluding any ADSs that may be sold or issued as part of the Option (as defined below)) and 2,850,000 underlying new Genmab shares, and (ii) that the public offering price for the ADSs issued as part of the Offering is $17.75 per ADS, corresponding to a subscription price of DKK 1,181.80 per underlying share issued at an exchange rate of DKK 6.6580 per US$1.00 on July 17, 2019. In connection with the pricing of the Offering the board of directors of Genmab has today decided to repeal the decision of July 9, 2019 to exercise its authorization to increase the share capital by up to 3,197,000 new shares underlying the ADSs and simultaneously in accordance with article 4A of Genmab's articles of association exercised an authorization granted by Genmab's annual general meeting held on April 10, 2018, to increase Genmab's share capital by issue of up to 3,277,500 new shares underlying the ADSs, of which 2,850,000 cover the shares being issued in connection with the Offering and 427,500 will cover shares in case the Option is exercised.

The registration statement on Form F-1 relating to the ADSs, including the preliminary prospectus forming a part thereof, has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). The offering of the ADSs is being made only by means of such prospectus.

BofA Merrill Lynch, Morgan Stanley and Jefferies are acting as joint book-running managers for the Offering. Guggenheim Securities and RBC Capital Markets are acting as joint lead-managers and Danske Markets, H.C. Wainwright & Co. and Kempen are acting as co-managers for the Offering. A copy of the preliminary prospectus and, when available, the final prospectus relating to the Offering may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email:  dg.prospectus_requests@baml.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone: 1-877-821-7388, or by email: Prospectus_Department@Jefferies.com. Copies of the preliminary prospectus and, when available, the final prospectus related to the Offering are also available, or will be available, at www.sec.gov. No Danish prospectus will be issued or offered.

This Company Announcement does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline and a number of proprietary next generation antibody technologies. Genmab has alliances with other leading pharmaceutical and biotechnology companies. Genmab is based in Copenhagen, Denmark.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the preliminary prospectus filed with the SEC. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 35

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
22 aug - 
Aktier/middag: Ambu sendes i dybet oven på regnskab i r..
22 aug - 
Aktier/åbning: Ambu hamres ned efter regnskab mens GN b..
22 aug - 
Aktier/tendens: GN og Ambu til eksamen i negativt marke..
Relateret debat
12:29 - 
*UPDATE: Morgan Stanley Initiates Genmab With Overweigh..
12:19 - 
Efter brud af 1500 tror jeg det komme til at gå stærkt ..
12:01 - 
Skal ærligt indrømme jeg har suppleret min i forvejen s..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
37
20 aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15
19 aug
GEN
https://ir.genmab.com/news-releases/news-release-details/daratumumab-abstracts-selected-presentation..
8
19 aug
GEN
Det altid fint at tage gevinst, og tillykke med den. Og fint du melde rent flag/ da du har været den..
7
19 aug
GEN
Ha-ha-ha...   I fredags kunne du - og mange andre, måtte man forstå - se store stigninger i den komm..
5
19 aug
GEN
Jeg har solgt alle mine Genmabs i den frie, tror stadig på gen men er bange for at vi skal ned gener..
5
19 aug
GEN
Han melder da rent flag, og må man ikke ændre menig ? Der kan være alle mulige grunde til hans besl..
3
22 aug
GEN
En analytiker som var gæst i Millionærklubben i dag, mente at Genmab ligger i stærk stigende trend. ..
2
20 aug
GEN
Ja der er mange gode nyheder fra Genmab for tiden :-) så man kan godt blive lidt nyheds resistent. M..
2
20 aug
GEN
Det er jo blot kendt viden, der bliver fremlagt paa en konference. Hvis man foelger lidt med, ved ma..
2

Vestas' største kinesiske konkurrent oplever dyk i overskuddet

23-08-2019 15:14:38
Den kinesiske vindmølleproducent Goldwind, som er verdens næststørste af sin slags efter Vestas, måtte i første halvår se sit overskud skrumpe med 22,6 pct. til 1,18 mia. yuan.Omsætningen for perioden er opgjort til 15,73 mia. yuan, fremgår det af Bloomberg News.Goldwind havde i 2018 en markedsandel globalt på 14,7 pct. - og var dermed nummer to efter Vestas med en andel på 22,2 pct.Nummer tre var..

Kina gengælder amerikansk told: Aktiefutures falder

Relaterede nyheder
23-08-2019 14:27:22
Kina vil indføre told på 5-10 pct. på amerikanske varer for yderligere 75 mia. dollar som en gengældelse af amerikanernes told på varer, som importeres fra Kina.Tolden indføres i to etaper henholdsvis 1. september og 1. december.Det skriver Bloomberg News.Ifølge det kinesiske medie Xinhua varsler Kina også en told på 25 pct. på amerikanske biler fra 15. december, og sojaimporten fra USA pålægges e..

Sydbank sænker Ambu-anbefaling - flere finanshuse retter kursmål efter nedjustering

23-08-2019 11:27:06
Sydbank ser en aktie i Ambu som "mindre attraktiv" end tidligere, efter medicoselskabet senest i denne uge skar i forventningerne til resultaterne for hele 2018/19.Derfor sættes anbefalingen ned til "hold" fra "køb", skriver Søren Løntoft Hansen, senioraktieanalytiker i Sydbank.- I kølvandet på strategiopdateringen i juni og gårsdagens melding om investeringerne i det direkte salg i USA har vi sæn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Trump efter Powells tale: Hvem er den største fjende?
2
Kina gengælder amerikansk told: Aktiefutures falder
3
Trump vil svare igen over for Kina senere fredag: Aktierne falder
4
Vestas' største kinesiske konkurrent oplever dyk i overskuddet
5
Fredagens aktier: Rockwool banket til bunds i urofyldt marked

Relaterede aktiekurser

Genmab A/S 1.376,00 -0,2% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. august 2019 13:53:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB2 - 2019-08-24 13:53:43 - 2019-08-24 13:53:43 - 1 - Website: OKAY